The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2026 | Genomic drivers and targeted therapy in smoking-related lung cancer
Maria Teresa Landi, MD, PhD, National Cancer Institute, Bethesda, MD, comments on the complexities of lung adenocarcinoma in smokers, highlighting the importance of targeted therapies for EGFR mutations, as well as other drivers such as ALK, ROS1, and RET fusions, and TP53 mutations. These genetic alterations can impact the aggressivity of the tumor and its response to treatment, and the cell of origin may be crucial in developing effective treatment strategies. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
